Back to top
more

Chemours (CC)

(Delayed Data from NYSE)

$27.69 USD

27.69
1,075,019

+0.37 (1.35%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $27.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Chemical - Diversified

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

How to Find Strong Basic Materials Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Are Options Traders Betting on a Big Move in Chemours (CC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.

Here's Why You Should Hold Onto Chemours (CC) Stock For Now

by Zacks Equity Research

Chemours (CC) gains on strong execution, continued Opteon adoption and its efforts to reduce costs amid headwinds from demand weakness.

Chemours (CC) Benefits From Opteon Adoption Amid Demand Woes

by Zacks Equity Research

Although Chemours (CC) is being challenged by softer demand in certain businesses, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.

Here's Why You Should Retain Chemours (CC) in Your Portfolio

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.

Chemours (CC) Announces Development of New Specialty Fluid

by Zacks Equity Research

Chemours' (CC) introduction of Opteon 2P50 is a critical step in positioning the company to meet a growing challenge brought on by a new era of data transmission.

Cabot (CBT) Joins US Energy Department's Better Plants Program

by Zacks Equity Research

Cabot (CBT) believes that this engagement with the DOE will help the company boost its energy efficiency performance.

Chemours (CC) Q2 Earnings Beat, Titanium Technologies Hurt Sales

by Zacks Equity Research

Chemours' (CC) Titanium Technologies sales were hurt by lower volumes due to weaker demand in all regions in Q2.

Methanex (MEOH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Methanex (MEOH) delivered earnings and revenue surprises of 9.09% and 4.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Huntsman (HUN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Huntsman (HUN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Titanium Technologies Unit Hurt Chemours (CC) Q2 Earnings?

by Zacks Equity Research

Slow demand recovery in the Titanium Technologies segment is expected to have weighed on Chemours' (CC) performance in the second quarter.

Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline

by Zacks Equity Research

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemours (CC) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Chemours (CC) benefits from strong Opteon demand, effective execution, and its cost-reduction and pricing actions.

Chemours (CC) Stock Up 16% in 3 Months: What's Driving It?

by Zacks Equity Research

Chemours (CC) gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.

Chemours (CC) Gains on Opteon Adoption Amid Demand Woes

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.

Chemours (CC) to Divest Glycolic Acid Business to PureTech

by Zacks Equity Research

Chemours (CC) believes that its Glycolic Acid portfolio complements PureTech's growth strategy.

Strength Seen in Chemours (CC): Can Its 24.1% Jump Turn into More Strength?

by Zacks Equity Research

Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Hold Onto Chemours (CC) Stock for Now

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from demand weakness in certain businesses, it gains on healthy Opteon adoption and its pricing actions.

Chemours (CC) Extends Capacity to Meet Customers' Needs

by Zacks Equity Research

Chemours (CC) offers a portfolio of HFO-1336mzzZ-based products that are more environmentally friendly than non-HFO alternatives.

Chemours' (CC) Q1 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Lower volumes and currency headwinds on a year-over-year basis, partly offset by higher pricing, impact Chemours' (CC) results in the first quarter.

Are Investors Undervaluing Chemours (CC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Chemours (CC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Chemours (CC) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of 58.06% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Methanex (MEOH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Methanex (MEOH) delivered earnings and revenue surprises of 20.65% and 6.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Northern Technologies (NTIC) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Northern Technologies (NTIC) delivered earnings and revenue surprises of -44.44% and 10.44%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?